Garcia-Echeverria C - Search Results

1

Molecular characterization of the hdm2-p53 interaction.

Böttger A, Böttger V, Garcia-Echeverria C, Chène P, Hochkeppel HK, Sampson W, Ang K, Howard SF, Picksley SM, Lane DP. Böttger A, et al. J Mol Biol. 1997 Jun 27;269(5):744-56. doi: 10.1006/jmbi.1997.1078. J Mol Biol. 1997. PMID: 9223638

2

A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines.

Chène P, Fuchs J, Bohn J, García-Echeverría C, Furet P, Fabbro D. Chène P, et al. J Mol Biol. 2000 May 26;299(1):245-53. doi: 10.1006/jmbi.2000.3738. J Mol Biol. 2000. PMID: 10860736

3

Identification of novel mdm2 binding peptides by phage display.

Böttger V, Böttger A, Howard SF, Picksley SM, Chène P, Garcia-Echeverria C, Hochkeppel HK, Lane DP. Böttger V, et al. Oncogene. 1996 Nov 21;13(10):2141-7. Oncogene. 1996. PMID: 8950981

4

Comparative study of the p53-mdm2 and p53-MDMX interfaces.

Böttger V, Böttger A, Garcia-Echeverria C, Ramos YF, van der Eb AJ, Jochemsen AG, Lane DP. Böttger V, et al. Oncogene. 1999 Jan 7;18(1):189-99. doi: 10.1038/sj.onc.1202281. Oncogene. 1999. PMID: 9926934

5

Coupling of the antennapedia third helix to a potent antagonist of the p53/hdm2 protein-protein interaction.

García-Echeverría C, Furet P, Chène P. García-Echeverría C, et al. Bioorg Med Chem Lett. 2001 Aug 20;11(16):2161-4. doi: 10.1016/s0960-894x(01)00394-8. Bioorg Med Chem Lett. 2001. PMID: 11514160

6

Study of the cytotoxic effect of a peptidic inhibitor of the p53-hdm2 interaction in tumor cells.

Chène P, Fuchs J, Carena I, Furet P, García-Echeverría C. Chène P, et al. FEBS Lett. 2002 Oct 9;529(2-3):293-7. doi: 10.1016/s0014-5793(02)03362-8. FEBS Lett. 2002. PMID: 12372616 Free article.

7

Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53.

García-Echeverría C, Chène P, Blommers MJ, Furet P. García-Echeverría C, et al. J Med Chem. 2000 Aug 24;43(17):3205-8. doi: 10.1021/jm990966p. J Med Chem. 2000. PMID: 10966738 No abstract available.

8

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.

Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, García-Echeverría C. Maira SM, et al. Mol Cancer Ther. 2008 Jul;7(7):1851-63. doi: 10.1158/1535-7163.MCT-08-0017. Epub 2008 Jul 7. Mol Cancer Ther. 2008. PMID: 18606717

9

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.

Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, Brachmann S, Fritsch C, Dorsch M, Chène P, Shoemaker K, De Pover A, Menezes D, Martiny-Baron G, Fabbro D, Wilson CJ, Schlegel R, Hofmann F, García-Echeverría C, Sellers WR, Voliva CF. Maira SM, et al. Mol Cancer Ther. 2012 Feb;11(2):317-28. doi: 10.1158/1535-7163.MCT-11-0474. Epub 2011 Dec 21. Mol Cancer Ther. 2012. PMID: 22188813

10

Dual specificity of Src homology 2 domains for phosphotyrosine peptide ligands.

Gay B, Furet P, García-Echeverría C, Rahuel J, Chène P, Fretz H, Schoepfer J, Caravatti G. Gay B, et al. Biochemistry. 1997 May 13;36(19):5712-8. doi: 10.1021/bi962642y. Biochemistry. 1997. PMID: 9153411

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

127 results

Search Page